Endologix (ELGX) has innovated in the medical device space with its Ventana product expanding the market and the
Nellix products presenting significant growth prospects after receiving regulatory approval in Europe, says Chris Cooley, Managing Director at Stephens Inc.
“In Europe, they are here today. Specifically Nellix began commercialization during the June calendar quarter. We think Ventana will enter the European market in the second half of next year, 2014. For us here in the States, they are further out. These products, realistically assuming standard FDA timeline, will not be available until the end of 2015, early 2016,” Cooley said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
Cooley says the Ventana and Nellix commercialization in Europe presents significant opportunities for growth, with topline growth in the double digits over the next three years.
“Their pipeline, though, is the real excitement here, and when we think about it, there is one device, Ventana, which basically has the opportunity to expand the market by upwards of $400 million; it’s about a $2.0 billion to $2.2 billion market today. And then Nellix, which just received a CE mark in Europe, really has the chance to change the game in the way that we think about endovascular approaches versus open surgical repair, and we see a very significant growth trajectory there; core top line growing in excess of 25% over the next three years,” Cooley said.
Globus Medical Inc (GMED) Has Opportunity for Growth as It Expands Into Trauma
November 02, 2015
Fidelity National Information Services (FIS) Expands in Europe
June 22, 2015
Zimmer Holdings (ZMH) Grows Volumes for Hip and Knee Orthopedic Medical Devices
March 15, 2013
The Latest in Medical Devices
March 20, 2008
Medical Devices Pick: CombiMatrix
September 29, 2008
